Overview Pharmacodynamics of Omiganan (CLS001) in Patients With Atopic Dermatitis Status: Completed Trial end date: 2015-11-01 Target enrollment: Participant gender: Summary To assess the pharmacodynamics, safety/tolerability, and efficacy of omiganan in patients with mild to moderate atopic dermatitis (AD). Phase: Phase 2 Details Lead Sponsor: Cutanea Life Sciences, Inc.Maruho Co., Ltd.